The Accelerator for Translational Biosciences at The Hamner Institutes for Health Sciences provides emerging companies with access to a research facility with state-of-the-art equipment, as well as world-class scientific and business development support. The Accelerator is a unique resource for small companies that provides substantial infrastructure to assist their commercialization efforts. Furthermore, the Accelerator fosters opportunities to develop collaborative research and educational programs among The Hamner, academia, industry, and government. Partnerships build shared resources and increase funding opportunities, which add value for each of the participants. This allows The Hamner, in collaboration with its institutional partners, to accelerate the commercialization of new technologies aimed at improving human health.
Current Hamner Accelerator Companies
b3bio, an RNA therapeutics company, joined the Accelerator in early 2008. The goal of the company, utilizing technology licensed from Duke University and the University of Texas at Austin, is to develop an entirely new class of medicines using small RNA molecules to target individual cells and tissues with remarkable precision. If successful, this technology could be used to treat cancer, metabolic disease, inflammation, and infection, and will dramatically improve upon current treatments by reducing unwanted side effects.
Biomedomics, Inc. (http://www.biomedomics.com/)
Biomedomics, the first company to join the Hamner’s Accelerator, develops advanced medical diagnostic tools based on multiplexed genomics and proteomics detection technologies for use in the rapidly growing field of personalized medicine. BioMedomics already has developed several unique biomarker reagent products and has begun to market a biosensor system for advanced cell assay applications.
Chaperone Therapeutics, Inc. (http://www.chaperonetherapeutics.com/)
Chaperone Therapeutics, Inc. ("Chaperone") is an early-phase pharmaceutical company that is developing drugs to treat diseases associated with abnormal protein folding and aggregation. Many neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, prion diseases, ALS (Lou Gehrig's Disease) and Huntington's disease are characterized by the abnormal aggregation of proteins in individuals with environmental exposure to proteotoxic stress or genetic vulnerability to the disease. Proteins that guide correct protein folding, chaperones, function as the cellular quality control mechanism to correct protein misfolding and to protect neurons from cell death. The master control for turning on the chaperone response in humans is the Heat Shock Transcription Factor 1 (HSF1). Chaperone is developing novel chemicals that activate HSF1, thereby elevating the body's natural protein folding capability to target diseases of misfolding, thereby ameliorating neuronal dysfunction and neuronal cell death.
Triangle Research Labs, LLC (http://www.triangleresearchlabs.com/)
Triangle Research Labs (TRL) produces high quality hepatocytes for use in pre-clinical ADMETox applications. TRL provides both human and animal, fresh and cryopreserved hepatocytes, and their relevant media. Additionally, TRL distributes GenoMembrane Transporter Products and the Nexcelom CelloMeter Vision - HepatoMeter. TRL has decades of experience in the hepatic sciences and is a leader in quality and service in the business.
For more information on the Hamner Biosciences Accelerator, please submit the form on the Contact Us page, with “Biosciences Accelerator” selected from the drop-down menu under “Interest.”